Logo image of TMDX

TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

USA - NASDAQ:TMDX - US89377M1099 - Common Stock

126.15 USD
+1 (+0.8%)
Last: 9/23/2025, 11:12:58 AM
Fundamental Rating

6

Overall TMDX gets a fundamental rating of 6 out of 10. We evaluated TMDX against 190 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes TMDX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

TMDX had positive earnings in the past year.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

TMDX's Return On Assets of 8.05% is amongst the best of the industry. TMDX outperforms 91.05% of its industry peers.
TMDX has a Return On Equity of 22.53%. This is amongst the best in the industry. TMDX outperforms 94.74% of its industry peers.
With an excellent Return On Invested Capital value of 7.25%, TMDX belongs to the best of the industry, outperforming 83.16% of the companies in the same industry.
Industry RankSector Rank
ROA 8.05%
ROE 22.53%
ROIC 7.25%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

With an excellent Profit Margin value of 13.49%, TMDX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
TMDX has a better Operating Margin (14.41%) than 84.21% of its industry peers.
TMDX has a Gross Margin of 59.79%. This is comparable to the rest of the industry: TMDX outperforms 60.00% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
Industry RankSector Rank
OM 14.41%
PM (TTM) 13.49%
GM 59.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

TMDX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
TMDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

TMDX has an Altman-Z score of 5.39. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX has a Altman-Z score of 5.39. This is amongst the best in the industry. TMDX outperforms 80.53% of its industry peers.
The Debt to FCF ratio of TMDX is 29.44, which is on the high side as it means it would take TMDX, 29.44 years of fcf income to pay off all of its debts.
TMDX's Debt to FCF ratio of 29.44 is fine compared to the rest of the industry. TMDX outperforms 67.89% of its industry peers.
TMDX has a Debt/Equity ratio of 1.61. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.61, TMDX is not doing good in the industry: 82.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF 29.44
Altman-Z 5.39
ROIC/WACC0.9
WACC8.03%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 9.86 indicates that TMDX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.86, TMDX belongs to the best of the industry, outperforming 92.11% of the companies in the same industry.
TMDX has a Quick Ratio of 9.10. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
TMDX has a Quick ratio of 9.10. This is amongst the best in the industry. TMDX outperforms 91.58% of its industry peers.
Industry RankSector Rank
Current Ratio 9.86
Quick Ratio 9.1
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4725.00%, which is quite impressive.
The Revenue has grown by 48.09% in the past year. This is a very strong growth!
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)4725%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.86%
Revenue 1Y (TTM)48.09%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%37.68%

3.2 Future

Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 49.75% on average per year.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.19% yearly.
EPS Next Y138.21%
EPS Next 2Y66.18%
EPS Next 3Y53.31%
EPS Next 5Y49.75%
Revenue Next Year39.73%
Revenue Next 2Y29.87%
Revenue Next 3Y25.77%
Revenue Next 5Y21.19%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 -6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 65.36, TMDX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 67.37% of the companies listed in the same industry.
TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
Based on the Price/Forward Earnings ratio of 45.23, the valuation of TMDX can be described as expensive.
TMDX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 70.00% of the companies in the same industry.
TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 65.36
Fwd PE 45.23
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 67.89% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than 67.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 247.84
EV/EBITDA 43.63
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.31% in the coming years.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y66.18%
EPS Next 3Y53.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSMEDICS GROUP INC

NASDAQ:TMDX (9/23/2025, 11:12:58 AM)

126.15

+1 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners121.6%
Inst Owner Change-6.21%
Ins Owners2.98%
Ins Owner Change2.28%
Market Cap4.30B
Analysts81.25
Price Target149.43 (18.45%)
Short Float %25.01%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.71%
Min EPS beat(2)100.04%
Max EPS beat(2)167.38%
EPS beat(4)3
Avg EPS beat(4)55.99%
Min EPS beat(4)-59.86%
Max EPS beat(4)167.38%
EPS beat(8)6
Avg EPS beat(8)145.25%
EPS beat(12)10
Avg EPS beat(12)114.95%
EPS beat(16)11
Avg EPS beat(16)83.13%
Revenue beat(2)2
Avg Revenue beat(2)9.07%
Min Revenue beat(2)4.34%
Max Revenue beat(2)13.8%
Revenue beat(4)3
Avg Revenue beat(4)4.75%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.8%
Revenue beat(8)7
Avg Revenue beat(8)11.77%
Revenue beat(12)11
Avg Revenue beat(12)15.17%
Revenue beat(16)14
Avg Revenue beat(16)17.24%
PT rev (1m)-2.98%
PT rev (3m)9.33%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)13.11%
EPS NY rev (1m)0%
EPS NY rev (3m)33.88%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)2.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.59%
Valuation
Industry RankSector Rank
PE 65.36
Fwd PE 45.23
P/S 8.09
P/FCF 247.84
P/OCF 37.31
P/B 13.52
P/tB 14.12
EV/EBITDA 43.63
EPS(TTM)1.93
EY1.53%
EPS(NY)2.79
Fwd EY2.21%
FCF(TTM)0.51
FCFY0.4%
OCF(TTM)3.38
OCFY2.68%
SpS15.58
BVpS9.33
TBVpS8.93
PEG (NY)0.47
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.05%
ROE 22.53%
ROCE 9.18%
ROIC 7.25%
ROICexc 13.96%
ROICexgc 14.41%
OM 14.41%
PM (TTM) 13.49%
GM 59.79%
FCFM 3.27%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF 29.44
Debt/EBITDA 5.09
Cap/Depr 412.74%
Cap/Sales 18.43%
Interest Coverage 250
Cash Conversion 114.93%
Profit Quality 24.21%
Current Ratio 9.86
Quick Ratio 9.1
Altman-Z 5.39
F-Score7
WACC8.03%
ROIC/WACC0.9
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4725%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.86%
EPS Next Y138.21%
EPS Next 2Y66.18%
EPS Next 3Y53.31%
EPS Next 5Y49.75%
Revenue 1Y (TTM)48.09%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%37.68%
Revenue Next Year39.73%
Revenue Next 2Y29.87%
Revenue Next 3Y25.77%
Revenue Next 5Y21.19%
EBIT growth 1Y6324.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.38%
FCF growth 1Y142.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y451.66%
OCF growth 3YN/A
OCF growth 5YN/A